8/9/2019 6:32:50 AM
Epizyme Q2 Net Loss Attributable To Common Stockholders $48.5 Mln Or $0.53/Shr Vs $29.1 Mln Or $0.42/Shr Last Year
7/25/2019 6:42:10 AM
Epizyme Announces FDA Filing Acceptance Of NDA And Priority Review For Tazemetostat For Epithelioid Sarcoma
6/12/2019 3:58:31 PM
Wedbush Reiterates Epizyme, Inc. (EPZM) At Outperform With $21 Price Target
6/3/2019 6:35:41 AM
Epizyme Reports Updated Data From Phase 2 Trial Of Tazemetostat For Epithelioid Sarcoma At 2019 ASCO Annual Meeting
5/30/2019 6:35:01 AM
Epizyme Submits NDA To FDA For Tazemetostat For Epithelioid Sarcoma Treatment
4/10/2019 9:09:08 AM
Wedbush Reiterates Epizyme, Inc. (EPZM) At Outperform With $21 Price Target
2/26/2019 6:37:41 AM
Epizyme Q4 Net Loss $22.9 Mln Or $0.29/Shr Vs Loss $36.2 Mln Or $0.52/Shr Last Year
1/4/2019 6:33:38 AM
Epizyme Provides Pipeline Updates And 2019 Guidance
12/18/2018 6:34:01 AM
Epizyme Earns $8 Mln Milestone Payment From GlaxoSmithKline
11/15/2018 6:32:51 AM
Boehringer Ingelheim And Epizyme Announce Worldwide Collaboration To Develop Novel Epigenetic Oncology Therapies
11/5/2018 9:23:18 AM
Wedbush Is Increasing Epizyme, Inc. (EPZM) FY19 Estimate To -1.95 From -2.10
11/5/2018 9:23:04 AM
Wedbush Is Increasing Epizyme, Inc. (EPZM) FY18 Estimate To -1.93 From -1.99
11/5/2018 9:22:49 AM
Wedbush Is Increasing Epizyme, Inc. (EPZM) Q4 18 Estimate To -0.48 From -0.51
11/5/2018 9:22:14 AM
Wedbush Reiterates Epizyme, Inc. (EPZM) At Outperform With $21 Price Target
11/2/2018 6:37:43 AM
Epizyme Q3 Net Loss $37.5 Mln Or $0.54/Shr Vs Loss Of $37.6 Mln Or $0.63/Shr Last Year
10/22/2018 5:01:12 AM
Epizyme Reports Positive Data On Tazemetostat In Epithelioid Sarcoma From Its Phase 2 Trial Cohort At ESMO
10/10/2018 6:46:10 AM
Epizyme To Present Updated Data On Tazemetostat From Full Phase 2 Study Cohort In Epithelioid Sarcoma At ESMO
10/5/2018 4:06:40 PM
Epizyme Closes Public Offering Of 9.58 Mln Shares Of Common Stock At $9/share